

RCT-TCZ-COVID-19 – Salvarani C, et al. *JAMA Intern Med* 2021 (Published: Oct 20, 2020)

Study Design	Multicenter, open-label RCT - Severe COVID-19 - (1:1)	
Location	Italy – 24 hospitals	
Inclusion	Severe COVID-19 with PaO ₂ /FiO ₂ ratio 200-300 and inflammatory phenotype defined by fever and elevated C-reactive protein (10 mg/dL and/or increased level to at least twice admission measurement)	
Exclusion	ICU admission (invasive or noninvasive mechanical ventilation)	
Intervention	Tocilizumab 8 mg/kg IV (up to 800 mg), followed by second dose after 12 h	
Control	Standard of care	
	Tocilizumab n=60	Control n=63
Primary Composite Outcome		
Clinical Worsening within 14 days since randomization *	17 (28.3%)	17 (27%)
Secondary Outcomes		
14- & 30-day mortality	1 (1.7%) - 2 (3.3%)	1 (1.6%) - 1 (1.6%)
14- & 30-day ICU admission	6 (10.0%) - 6 (10.0%)	5 (7.9%) - 5 (7.9%)
Comments:	* Clinical worsening definition: 1) ICU admission requiring MV; 2) PaO ₂ /FiO ₂ ratio < 150; 3) Death from any cause - Unclear number of patients treated with corticosteroids in the different groups	
Abbreviations:	CRP, C-reactive protein; ICU, intensive care unit; PaO ₂ /FiO ₂ , partial pressure of arterial oxygen to fraction of inspired oxygen; RCT, randomized controlled trial	